NCT03299452: Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor

NCT03299452
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT03299452

Comments are closed.

Up ↑